89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Strategic Positioning | Learn about pegoza's potential synergies with GLP-1 therapies and its promising efficacy in advanced MASH stages, positioning 89Bio for future growth |
Financial Outlook | Analyst price targets for 89Bio range from $12 to $29, reflecting varied perspectives on pegoza's market potential and development progress |
Market Dynamics | Delve into the competitive MASH treatment landscape, where pegoza's unique benefits could differentiate it from emerging GLP-1 therapies |
Pegoza's Promise | Explore 89Bio's lead candidate pegozafermin, showing potential in treating Metabolic Associated Steatohepatitis (MASH) with antifibrotic and cardiometabolic benefits |
Metrics to compare | ETNB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETNBPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.9x | −5.8x | −0.7x | |
PEG Ratio | 0.07 | 0.05 | 0.00 | |
Price / Book | 3.0x | 2.7x | 2.6x | |
Price / LTM Sales | - | 33.0x | 3.2x | |
Upside (Analyst Target) | 228.1% | 158.9% | 44.5% | |
Fair Value Upside | Unlock | 9.3% | 6.6% | Unlock |